Brazil's Anti-Smoking Project in Amazon: Progress and Challenges

Regulations by 2FIRSTS.ai
May.16.2024
Brazil's Anti-Smoking Project in Amazon: Progress and Challenges
Representatives from Amazonas met at FCecon to discuss advancing the tobacco control project, aiming to reduce smoking rates.

According to Brazilian media reports on May 15th, representatives from the local government of Amazonas and coordinators of national and state-level tobacco control programs met at the Amazonas State Cancer Control Foundation (FCecon) to discuss how to further advance the project. The meeting was attended by Gerson Mourão, director of the Amazonas State Cancer Control Foundation, and representatives from the Amazonas State Health Department (SES-AM).

 

The National Tobacco Control Program (PNCT) is a joint initiative of the Brazilian Ministry of Health and the Brazilian National Cancer Institute (Inca) with a 20-year history. The aim of the program is to reduce smoking rates and smoking- related death rates. In the Amazon region, these activities are primarily carried out by the Amazonas State Cancer Control Center Foundation (FCecon).

 

Aristóteles Alencar, the state coordinator of the Amazonas Tobacco Control Program, stated that Amazonas ranked third in the country for the number of tobacco consumers who quit smoking, achieving remarkable results. He mentioned that the visit from the team of the Brazilian National Cancer Institute (Inca) was to understand the effective actions that have led to Amazonas reaching high quit smoking rates.

 

He pointed out, "Despite the vast expanse of the region and the many logistical challenges, the Brazilian National Cancer Institute (Inca) chose the Amazonas state as its research subject because we have achieved the lowest smoking rates nationwide. Our model can be replicated in other places. The key factors to success include the Amazonas State Cancer Control Center Foundation disseminating information to the public, as well as collaborating with the city and state education departments (Seduc and Semed) to host events promoting anti-smoking campaigns with children, and so on.

 

Alanaca added that, currently, the project is in its second phase. The project aims to expand anti-smoking activities to other areas and places a strong emphasis on understanding the unique environmental factors of each location in order to improve the health of the local population. The purpose of this meeting is to gather the strength of various organizations and individuals to enhance the effectiveness and sustainability of the anti-smoking project. The meeting also aims to raise awareness among regional representatives of the significant economic costs of the diseases and loss of life caused by smoking.

 

This type of epidemic has caused losses of up to 125 billion reais to our country, and we can only recover 10% of that amount from taxes. The amount itself is already unacceptable," expressed Alencar.

 

In addition, consultants Lucas Cabral and Érica Cavalcante from the Brazilian National Cancer Institute emphasized the efforts of institutions such as the Brazilian Ministry of Health (MS) in safeguarding public health and combating tobacco consumption.

 

Lucas Cabral stated: "We need to learn and understand from ourselves as the foundation for improving and integrating public policies, which are implemented by the Brazilian Ministry of Health and the Brazilian National Cancer Institute.

 

The project aims to ensure the strength of domestic tobacco control actions while also taking sustainability into consideration.

 

Due to limited health budget, we first chose five states, one in each region. Now, through discussions with state coordinating bodies, we hope to understand their weaknesses and strengths, and together advance anti-smoking campaigns," explained Kaval Kant.

 

Next, a team from the Brazilian National Cancer Institute and local partners will hold a meeting with professionals responsible for assisting smokers in quitting. They will discuss topics such as tobacco prevention, creating smoke-free environments, and treatment for e-cigarette use.

 

We welcome news tips, article submissions, interview requests, or comments on this piece.

Please contact us at info@2firsts.com, or reach out to Alan Zhao, CEO of 2Firsts, on LinkedIn


Notice

1.  This article is intended solely for professional research purposes related to industry, technology, and policy. Any references to brands or products are made purely for objective description and do not constitute any form of endorsement, recommendation, or promotion by 2Firsts.

2.  The use of nicotine-containing products — including, but not limited to, cigarettes, e-cigarettes, nicotine pouchand heated tobacco products — carries significant health risks. Users are responsible for complying with all applicable laws and regulations in their respective jurisdictions.

3.  This article is not intended to serve as the basis for any investment decisions or financial advice. 2Firsts assumes no direct or indirect liability for any inaccuracies or errors in the content.

4.  Access to this article is strictly prohibited for individuals below the legal age in their jurisdiction.

 

Copyright

 

This article is either an original work created by 2Firsts or a reproduction from third-party sources with proper attribution. All copyrights and usage rights belong to 2Firsts or the original content provider. Unauthorized reproduction, distribution, or any other form of unauthorized use by any individual or organization is strictly prohibited. Violators will be held legally accountable.

For copyright-related inquiries, please contact: info@2firsts.com

 

AI Assistance Disclaimer

 

This article may have been enhanced using AI tools to improve translation and editorial efficiency. However, due to technical limitations, inaccuracies may occur. Readers are encouraged to refer to the cited sources for the most accurate information.

We welcome any corrections or feedback. Please contact us at: info@2firsts.com

GAO Audit Finds Nearly 132,000 FDA Tobacco Applications Waiting an Average 1,266 Days as Nicotine Pouch Pilot Practices Move Into Vape PMTA Reviews
GAO Audit Finds Nearly 132,000 FDA Tobacco Applications Waiting an Average 1,266 Days as Nicotine Pouch Pilot Practices Move Into Vape PMTA Reviews
A U.S. Government Accountability Office audit found that 131,915 tobacco product applications submitted to the FDA since 2018 remained without a final review as of December 31, 2025, with pending applications waiting an average of 1,266 days. GAO also found FDA lacks the data needed to systematically determine whether scientific reviews meet applicable timelines. HHS agreed to upgrade the agency's tracking systems. At the same time, FDA has begun applying lessons from its nicotine pouch PMTA pilot to e-cigarette reviews, while changes to enforcement policy and electronic submissions are making the specific stage of a PMTA increasingly relevant to market access.
FDA
Oct.03
PMI Expands U.S. ZYN Portfolio With New 1.5 mg and 8 mg Strengths, Moves Toward a Unified 20-Pouch-Per-Can Format
PMI Expands U.S. ZYN Portfolio With New 1.5 mg and 8 mg Strengths, Moves Toward a Unified 20-Pouch-Per-Can Format
Philip Morris International is expanding its U.S. ZYN nicotine pouch portfolio with new 1.5 mg and 8 mg strengths and plans to move its core 3 mg and 6 mg dry-pouch products from 15 to 20 pouches per can in the fourth quarter of 2026. ZYN ULTRA is also commercially available, with FDA authorization covering 10 products at 9 mg and one 11 mg Smooth product. PMI U.S. lists the new 1.5 mg and 8 mg strengths as commercially available, but as of September 10 they do not appear on the FDA’s public authorization list. Public materials do not identify which PMTA submissions cover the two new strengths or their current review status.
Sep.11
U.S. Judge Stays Helix, NJOY Challenge to FDA PMTA Rule Pending New Rulemaking Court Stays Altria's Helix, NJOY Challenge to PMTA Rule as FDA Prepares New Rulemaking
U.S. Judge Stays Helix, NJOY Challenge to FDA PMTA Rule Pending New Rulemaking Court Stays Altria's Helix, NJOY Challenge to PMTA Rule as FDA Prepares New Rulemaking
A federal judge in Texas on Oct. 8 granted a joint request by the FDA and plaintiffs including Altria subsidiaries Helix Innovations and NJOY to stay litigation challenging the agency's 2021 PMTA rule. The court cited FDA's anticipated rulemaking concerning the regulation at issue. FDA announced on Sept. 28 that it intends to reassess the PMTA framework and could initiate new rulemaking to replace it. The parties must file a joint status report within 45 days and every 45 days thereafter. A motion by three Reynolds American companies to intervene remains pending.
Regulations
Oct.10
Germany's Four-Year Tobacco Tax Plan Heads to Parliament as BAT, JTI and PMI Push for Changes
Germany's Four-Year Tobacco Tax Plan Heads to Parliament as BAT, JTI and PMI Push for Changes
Germany's parliament is scheduled to hold a first reading of amendments to the Tobacco Tax Act on September 24. The government plans annual tax increases from 2027 through 2030 covering cigarettes, heated tobacco, vaping liquids and other categories. It expects the reform to generate €756 million in additional revenue in 2027, rising to €3.589 billion in additional annual revenue by 2030. Ahead of the parliamentary debate, the German Association of the Tobacco Industry and Novel Products, or BVTE, launched the "Tabaksteuer mit Augenmaß" campaign backed by BAT, JTI, Philip Morris, Reemtsma and wholesale and retail groups.
Sep.23
Reynolds Seeks to Join Altria Lawsuit Challenging FDA PMTA Rule and Calculation of 180-Day Deadline
Reynolds Seeks to Join Altria Lawsuit Challenging FDA PMTA Rule and Calculation of 180-Day Deadline
Three R.J. Reynolds companies are seeking to intervene in a lawsuit filed by Altria subsidiaries Helix Innovations and NJOY challenging the FDA's 2021 PMTA final rule. The companies dispute how the agency uses Acceptance and Filing reviews and completeness determinations to establish when the Tobacco Control Act's 180-day decision period begins. Reynolds has also linked prolonged PMTA reviews to competition from unauthorized vaping products. The FDA, meanwhile, has been accelerating reviews and reducing its backlog.
Sep.14
Canada Considers Easing Pharmacy-Only Nicotine Pouch Sales Rules, Potentially Reopening Convenience Store Channel
Canada Considers Easing Pharmacy-Only Nicotine Pouch Sales Rules, Potentially Reopening Convenience Store Channel
Canada's federal government is considering changes to current restrictions on where nicotine pouches can be sold, potentially allowing authorized products to return to convenience stores and other general retail channels, although no decision has been made. Since 2024, emerging nicotine replacement therapy products such as nicotine pouches have been largely restricted to behind-the-counter pharmacy sales. Health Canada, meanwhile, continues to recall unauthorized and higher-strength nicotine pouches, indicating that the current discussion concerns retail access for authorized products rather than a broad relaxation of nicotine pouch regulation.
Sep.14